Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment ...

Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

Advances in critical care therapies for patients with cardiogenic shock (CS), including temporary mechanical circulatory support and multidisciplinary shock teams, have led to improved survival to ...

The current approach, which initiates medications and escalates to mechanical circulatory support, has not resulted in a ...

The following is a summary of “Patient Characteristics, Management and Long-term Outcomes of Patients with Cardiogenic Shock ...

Discover how heart centers across the country are improving patient outcomes and reducing mortality rates through innovative approaches and advanced therapies.

Cardiogenic shock occurs when the heart is not able to pump enough blood to generate adequate cardiac output to maintain normal blood pressure. This frequently occurs in the setting of a large ...

Are you searching for effective medications to treat 'Cardiogenic Shock'? This comprehensive guide provides the latest information on medications-both generic and branded-that are essential for ...

(NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment for early cardiogenic shock, at the Cardiovascular Clinical Trials Conference in Washington ...

Hospitals with a higher volume of percutaneous microaxial ventricular assist device implantation in the US have fewer deaths among cardiogenic shock patients.